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It has long been established that the Trypanosoma brucei TbAT1/P2 aminopurine transporter is involved in
the uptake of diamidine and arsenical drugs including pentamidine, diminazene aceturate and melarso-
prol. Accordingly, it was proposed that the closest Trypanosoma congolense paralogue, TcoAT1, might per-
form the same function in this parasite, and an apparent correlation between a Single Nucleotide
Polymorphism (SNP) in that gene and diminazene tolerance was reported for the strains examined. Here,
we report the functional cloning and expression of TcoAT1 and show that in fact it is the syntenic homo-
logue of another T. brucei gene of the same Equilibrative Nucleoside Transporter (ENT) family: TbNT10.
The T. congolense genome does not seem to contain a syntenic equivalent to TbAT1. Two TcoAT1 alleles,
differentiated by three independent SNPs, were expressed in the T. brucei clone B48, a TbAT1-null strain
that further lacks the High Afﬁnity Pentamidine Transporter (HAPT1); TbAT1was also expressed as a con-
trol. The TbAT1 and TcoAT1 transporters were functional and increased sensitivity to cytotoxic nucleoside
analogues. However, only TbAT1 increased sensitivity to diamidines and to cymelarsan. Uptake of [3H]-
diminazene was detectable only in the B48 cells expressing TbAT1 but not TcoAT1, whereas uptake of
[3H]-inosine was increased by both TcoAT1 alleles but not by TbAT1. Uptake of [3H]-adenosine was
increased by all three ENT genes. We conclude that TcoAT1 is a P1-type purine nucleoside transporter
and the syntenic equivalent to the previously characterised TbNT10; it does not mediate diminazene
uptake and is therefore unlikely to play a role in diminazene resistance in T. congolense.
 2013 Australian Society for Parasitology Published by Elsevier Ltd. All rights reserved.1. Introduction
The most common drug to treat animal trypanosomiasis in sub-
Saharan Africa is the diamidine compound diminazene aceturate
(DA) and the effective treatment of livestock with trypanocides re-
mains of the highest importance for farmers in the tsetse belt
where an estimated 46–62 million head of cattle are at risk of try-
panosomiasis (Swallow, 2000). Control of the disease is largely
either by vector control or chemotherapy, of which an estimated35 million doses are administered annually (Geerts and Holmes,
1998). However, the effectiveness of DA and the only other com-
mon drug for trypanosomiasis, isometamidium chloride, are threa-
tened by drug resistance (Geerts et al., 2001; Delespaux et al.,
2008a). In order to manage the situation effectively, it is necessary
to understand the resistance mechanism and devise predictive
tests that distinguish between drug sensitive and resistant popula-
tions (Delespaux et al., 2008a).
The diamidine trypanocides were developed in the late 1930s
(Lourie and Yorke, 1939) and as early as 1944 Hawking reported
that aromatic diamidines are actively accumulated by live but
not by dead Trypanosoma brucei to intracellular concentrations
up to three orders of magnitude higher than the extracellular con-
centration (Hawking, 1944). He proposed that the massive drug
accumulation, not observed in the surrounding blood cells, was
the basis of the selective trypanocidal action. A similar accumula-
tion, apparently energy dependent, has also been reported for DA
(Girgis-Takla and James, 1974; De Koning et al., 2004) and for
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used to treat human African trypanosomiasis (Delespaux and De
Koning, 2007). Dependent on the extracellular concentration,
about 50% of the uptake of pentamidine in T. b. brucei is mediated
by the TbAT1/P2 transporter (Carter et al., 1995; De Koning and
Jarvis, 2001; Bray et al., 2003). The rest is transported by a High
Afﬁnity Pentamidine Transporter (HAPT1) and a Low Afﬁnity Pent-
amidine Transporter (LAPT1) (De Koning, 2001, 2008). However,
the uptake of DA is almost exclusively through TbAT1/P2 (De Kon-
ing et al., 2004), with only a very minor contribution from HAPT1
(Teka et al., 2011). The most likely explanation for the differences
in DA and pentamidine transport is the ﬂexibility of the linker
chain between the pentamidine benzamidine ends, allowing the
molecule to assume many different conformations whereas the
diminazene structure is rigid, locking the benzamidine moieties
in a ﬁxed position.
There is abundant evidence that diamidine resistance in T. bru-
cei complex species is linked to loss of transport (Delespaux and De
Koning, 2007). A stilbamidine-resistant T. b. rhodesiense strain was
deﬁcient in accumulation of the drug (Fulton and Grant, 1955).
Loss of TbAT1/P2 and HAPT1 gives a high pentamidine resistance
phenotype in T. b. brucei (Bridges et al., 2007) and loss of the P2
aminopurine transport activity alone is sufﬁcient to give substan-
tial DA resistance in T. b. brucei (Matovu et al., 2003; De Koning
et al., 2004), Trypanosoma equiperdum (Barrett et al., 1995) and Try-
panosoma evansi (Witola et al., 2004). However, the most impor-
tant trypanosomatid pathogen for livestock in sub-Saharan Africa
is Trypanosoma congolense and it is important to establish whether
the same DA resistance model applies for this parasite. Addition-
ally, the need for novel chemotherapeutic and chemoprophylactic
tools for trypanosomiasis is grave, and given the range of diami-
dines available for development, understanding any mechanism
of resistance will aid the exploitation of new members of this class
of compounds. The most likely TbAT1 orthologue in the T. congo-
lense genome was identiﬁed as TcIL3000.5.2500 and it was named
TcoAT1 (Delespaux et al., 2006). A recent in-depth analysis of Try-
panosoma genomes conﬁrmed that it is closely related (Jackson,
2012). A Single Strand Conformation Polymorphism (SSCP) tech-
nique was used to try and establish whether TcoAT1 polymor-
phisms might be associated with a diminazene sensitivity
phenotype (Delespaux et al., 2006), using a single dose mouse test
(Eisler et al., 2001) to report on resistance. This analysis found a
strong correlation between SSCP pattern and drug sensitivity: out
of 26 T. congolense strains 14 DA-sensitive and 9 resistant strains
were correctly predicted using 20 mg/kg. The remaining 3 strains
were predicted to be resistant by SSCP pattern, but were classiﬁed
as sensitive by the mouse test, albeit with some infections relaps-
ing, particularly at 5 mg/kg DA (Delespaux et al., 2006). It was con-
cluded that TcoAT1 was likely to be equivalent to the AT1
transporters in T. brucei, T. equiperdum and T. evansi and this
seemed conﬁrmed with the detection of an Ile306Val polymor-
phism in some of the TcoAT1 alleles cloned from intermediate
and highly resistant strains. The presence of this SNP was investi-
gated by Restriction Fragment Length Polymorphism (RFLP) in all
26 strains and correlated perfectly with the observed resistance
phenotype (Delespaux et al., 2006); polymorphisms in TbAT1 have
been similarly associated with failure to transport melaminophe-
nyl arsenicals (Mäser et al., 1999; Matovu et al., 2001).
A further study on 11 T. congolense strains collected in Camer-
oon (Mamoudou et al., 2008) and 12 strains collected in Ethiopia
(Moti et al., 2012) showed all strains to be DA-resistant by the sin-
gle-dose mouse test and all the Cameroonian and only six of the
Ethiopian being classiﬁed as ‘resistant’ by TcoAT1 PCR–RFLP. How-
ever, these studies did not contain any ‘sensitive strains’ and thus
did not in themselves rule out the trivial explanation that the
TcoAT1 PCR–RFLP simply identiﬁed the dominant polymorphismin T. congolense strains of the regions investigated. The observation
that the RFLP-identiﬁed SNP was also common in T. congolense iso-
lated fromwildlife in areas with no history of prior trypanocide use
(Chitanga et al., 2011) does appear to show that this is a common
polymorphism and unlikely to be the result of drug pressure.
Therefore, the similarity between TcoAT1 and TbAT1, and the
apparent association with DA-resistance in T. congolense are tem-
pered by the lack of total correlation. Moreover, no functional
expression or characterization has been performed for this mem-
ber of Equilibrative Nucleoside Transporter (ENT) family. In order
to provide a deﬁnitive test on whether TcoAT1 is involved in
diamidine transport, and whether TcoAT1 mutations are involved
in resistance, we have expressed two separate TcoAT1 alleles
(‘sensitive’ and ‘resistant’) as well as TbAT1, in a well-character-
ised DA-resistant TbAT1 null strain of T. b. brucei (Bridges et al.,
2007).2. Materials and methods
2.1. Trypanosome strains and culturing
Bloodstream-form T. b. brucei strain B48 and its derivatives
were maintained as previously described (Bridges et al., 2007).
The B48 strain is derived from the Lister 427 strain, but lacks the
T. brucei AT-1 gene and the high afﬁnity pentamidine transporter
(Bridges et al., 2007).
2.2. Plasmid construction and transfection
The full TcoAT-1 (TcIL3000_9_2500) gene was ampliﬁed from
the sensitive T. congolense strain TRT12 (Delespaux et al., 2006)
and the resistant strain Alick 339 (Delespaux et al., 2008b) (both
isolated from cattle in Zambia), using the high-ﬁdelity proof-read-
ing polymerase Phusion (Finnzymes), with forward primer 50-
GGGCCCATGCTCGGTTTTGAATCC-30 and reverse primer 50-AGAT-
CTTTACCACTCTGGCAGGGCCT-30. The amplicons were ligated into
the pGEM-T Easy sub-cloning vector (Promega) and sequenced
using standard procedures.
The TcoAT1 gene from the sensitive and resistant strains was
then ligated into the expression vector pHD1336 (Biebinger et al.,
1997), to give pHDK45 and pHDK46 respectively. The TbAT1 gene
from T. brucei (Tb927.5.286b) was generated by high-ﬁdelity PCR
using Lister 427 strain gDNA, with forward primer 50- GGGCCCA
TGCTCGGGTTTGACTCA-30 and reverse primer 50- GGATCCC-
TACTTGGGAAGCCCCTC-30, and ligated into the pHD1336 expres-
sion vector to give pHDK44. All three constructs were linearised
with NotI prior to transfection; B48 parasites were washed into Hu-
man T Cell Solution for transfection using the desired cassette with
an Amaxa Nucleofector as described (Burkard et al., 2007). Trans-
fectants were grown and cloned out, by limiting dilution, in stan-
dard HMI-11 (Hirumi and Hirumi, 1989) containing 5 lg ml1
blasticidin S.
2.3. Drug sensitivity assays
Drug sensitivities were assessed using the dye resazurin (Alamar
blue) using a protocol adapted from Räz et al. (1997), as described
(Gould et al., 2008). Brieﬂy, drugs were serially-diluted in 100 ll
of complete HMI-11 media across two rows of a 96 well plate. Cul-
tures of bloodstream-form trypanosomes were diluted to 2  105 -
cells/ml in complete HMI-11, and 100 ll was added to all wells.
Plates were incubated for 48 h at 37 C/5% CO2, prior to the addition
of 20 ll of 5 mM resazurin sodium salt (Sigma–Aldrich) in PBS,
pH7.4. Plates were incubated for a further 24 h in the same
conditions, before ﬂuorescence was measured using a FLUOstar
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trations (IC50) were calculated using the sigmoidal curve algorithm
of Prism 5 (GraphPad). Experiments were performed independently
at least four times.
2.4. Transport assays
Uptake assays of [3H]-diminazene, [3H]-inosine and [3H]-aden-
osine were performed exactly as described (Wallace et al., 2002;
Natto et al., 2005). Brieﬂy, trypanosomes from late-log phase cul-
tures were washed into assay buffer (AB; 33 mM HEPES, 98 mM
NaCl, 4.6 mM KCl, 0.55 mM CaCl2, 0.07 mM MgSO4, 5.8 mM NaH2-
PO4, 0.3 mM MgCl2, 23 mM NaHCO3, 14 mM glucose, pH 7.3) and
resuspended at 108 cells ml1. One hundred microlitres of cell sus-
pension was incubated with either [Ring-3H]-DA (Perkin Elmer,
60.7 Ci/mmol), [2,8-3H]-adenosine (American Radiolabeled Chemi-
cals Inc, 40 Ci/mmol) or [8-3H]-Inosine (American Radiolabeled
Chemicals Inc., 20 Ci/mmol) in the presence or absence of unla-
beled substrate or other competitive inhibitors. Incubations were
stopped by the addition of 1 ml ice-cold unlabeled substrate
(1 mM in AB) and centrifugation through oil (13,000g; 1 min).
The cell pellet was transferred to a scintillation tube and radioac-
tivity was determined by liquid scintillation counting. The results
were plotted to equations for linear or non-linear regression using
Prism 5 (GraphPad) after correction for non-speciﬁc association of
radiolabel with the pellet, as described (Wallace et al., 2002).3. Results
3.1. Sequencing of TcoAT1 alleles
The TcoAT1 alleles were PCR-ampliﬁed from genomic DNA of
the TRT12 (‘sensitive’; Delespaux et al., 2006) and Alick339 (‘resis-
tant’; Delespaux et al., 2008b) T. congolense isolates, and cloned
into the pGEMT Easy vector prior to sequencing. From each strain,
four independent clones were sequenced; sequences were identi-
cal within a strain, consistent with homozygosity for TcoAT1 as
originally suggested by the PCR–RFLP (Delespaux et al., 2006;
Delespaux et al., 2008a,b); Alick339 is a cloned strain, previously
reported to be homozygous for the ‘resistant’ polymorphism
(Delespaux et al., 2008b). The nucleotide sequences of TcoAT1 al-
leles from a DA ‘sensitive’ and a ‘resistant strain’ were determined
and found to differ by 10 SNPs which do not affect the coding se-
quence, and 3 SNPs which cause amino acid alterations: Met75Thr,
Ala262Gly and Val306Ile (Supplementary Fig. S1). These alleles and
the T. brucei 427 TbAT1 gene were cloned into the pHD1336 expres-
sion vector and expressed in the DA-resistant T. brucei B48 strain.
Correct integration of the genes was established by PCR (not
shown).
3.2. Genomic analysis of ENT genes in African trypanosomes
The premise that the gene named TcoAT1 is equivalent to the
known diamidine transporter TbAT1 is based on it being the closest
T. congolense paralogue identiﬁed from a database of unassembled
(pre-genome) contigs. However, there is no syntenic equivalent of
TbAT1 (Tb927.5.286b) in the now-assembled T. congolense genome
(TriTrypDB.org). Indeed, TcoAT1 (TcIL3000.9.2500) is syntenic with
another of the T. brucei ENT family genes, Tb09.160.5480 (De
Koning et al., 2005), which is known as TbNT10 or AT-B. This gene
encodes a high afﬁnity purine nucleoside transporter (Sanchez
et al., 2004) that has been characterised in detail (Al-Salabi et al.,
2007) and is preferentially expressed in short-stumpy (Sanchez
et al., 2004) and procyclic (Al-Salabi et al., 2007; Spoerri et al.,
2007) forms of T. brucei. A syntenic equivalent is also present inthe T. b. gambiense genome, but not in Trypanosoma vivax or Leish-
mania species.
Fig. 1 shows a phylogenetic tree of ENT genes from T. b. brucei, T.
congolense, Trypanosoma cruzi, and T. vivax, indicating different
branches for nucleobase transporters, purine nucleoside transport-
ers (‘P1-type’) and ‘P2-type’ transporters. The diagram clearly
shows that all these species have nucleobase transporter genes,
several of which have been characterised by heterologous expres-
sion (Burchmore et al., 2003; Henriques et al., 2003) and P1-type
nucleoside transporters, of which multiple members also have
been functionally characterised (Sanchez et al., 1999, 2002; De
Koning et al., 2005), including TbNT10 (Al-Salabi et al., 2007; Spo-
erri et al., 2007). In the tree, TcoAT1 groups with the T. brucei P1-
type transporters, and is closely related to Tb09.160.5480
(TbNT10), as would be predicted from the synteny. Formally the
phylogenetic tree does not statistically differentiate between the
P1 and P2-type transporters, though as noted above all of the T.
b. brucei genes have been functionally conﬁrmed as one type or
the other. Therefore, the combination of clear synteny (with all
the other T. b. brucei P1-type transporters being physically located
on different chromosomes), and the phylogenetic grouping of
TcoAT1with the P1-type transporters strongly suggests that TcoAT1
is the T. congolense equivalent of TbNT10. In addition, a BLASTp
search using the TcoAT1 protein sequence as the query sequence
returned all the P1-type nucleoside transporters as the highest T.
b. brucei hits by maximum percentage identity, with TbNT10 having
one of the highest scores (67%; range of other P1-type transporters
identity is from 67% to 61%). TbAT1 had a maximum percentage
identity of 54% (Supplementary Table S1). From data currently
available, T. congolense does not seem to possess any P2-type trans-
porter genes.
3.3. Sensitivity of TcoAT1 and TbAT1-expressing clones to nucleoside
analogues and trypanocides
Functional expression of TbAT1 and TcoAT1 in the Tbb B48 clonal
line was tested using a series of cytotoxic adenosine analogues.
Fig. 2 shows that introduction of TbAT1 into this strain caused a
profound increase in sensitivity to tubercidin (7-deazaadenosine;
Fig. 2A), 50-deoxyadenosine (50-dAdo; Fig. 2B) and cordycepin (30-
deoxyadenosine; Fig. 2C), of 360 (P < 0.001), 20 (P < 0.01), and
23-fold (P < 0.01), respectively (n = 5). Expression of TcoAT1 (‘sensi-
tive allele’; TcoAT1S) also signiﬁcantly increased sensitivity to these
adenosine analogues, but by only 2–2.5-fold (all P < 0.05; n = 5).
Sensitivity to phenylarsine oxide (PAO), a lipophilic arsenic com-
pound, was unchanged in all strains (Fig. 2D).
The above results show that ENT transporters can be function-
ally expressed in the B48 strain and inﬂuence drug sensitivity.
We thus proceeded with testing sensitivity to a number of trypan-
ocides that have previously been shown to be substrates for
TbAT1/P2: diminazene, pentamidine and cymelarsan (Carter and
Fairlamb, 1993; Carter et al., 1995; De Koning and Jarvis, 1999,
2001; De Koning et al., 2004). As expected, the expression of TbAT1
in this strain greatly increased sensitivity to these drugs, by 219,
209 and 53-fold, respectively (all P < 0.01; Fig. 3A–C). However,
expression of either the ‘sensitive’ or ‘resistant’ allele of TcoAT1
did not alter drug sensitivity at all (Fig. 3). Sensitivity to PAO was
not signiﬁcantly different for any of the strains.
3.4. Transport of diminazene and of purine nucleosides by TcoAT1- and
TbAT1-expressing clones
The above results appear to show that TcoAT1 is unable to trans-
port anyof thediamidineormelaminophenyl arsenical drugs tested,
including diminazene. We therefore directly tested the uptake of
[3H]-diminazene. Introduction of TbAT1 into B48 trypanosomes
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0.123 ± 0.005 pmol (107 cells)1 s1 (n = 3; r2 = 0.99) compared to
0.0093 ± 0.0046 pmol (107 cells)1 s1 in the empty vector control,
whereas expression of TcoAT1S had no effect at all on the uptake rate
(0.0093 ± 0.0043; Fig. 4). However, both TcoAT1 alleles were clearlyfunctionally expressed in B48 as both mediated transport of [3H]-
inosine and [3H]-adenosine. Inosine uptake was highly signiﬁcantly
enhanced in B48 expressing TcoAT1S (P < 0.001), and to a slightly
lesser extent by TcoAT1R (P < 0.01); in contrast, expression of TbAT1
didnot change [3H]-inosine uptake (Fig. 5A), consistentwith the fact
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Fig. 3. Sensitivity of T. b. brucei bloodstream forms of various clonal lines to diminazene (A), pentamidine (B), cymelarsan (C) and phenylarsine oxide (D), as determined using
standard Alamar blue-based assay. All clonal strains were derived from the B48 line, which is highly resistant to diamidines and melaminophenyl arsenicals (Bridges et al.,
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Fig. 4. Diminazene uptake in transformed T. b. brucei B48. B48 cells transformed
with either vector without insert (circles), TbAT1 (squares) or TcoAT1S (up triangles)
were incubated with 0.1 lM [3H]-diminazene with (open symbols) or without
(ﬁlled symbols) 1 mM unlabeled diminazene aceturate for up to 5 min as indicated.
Symbols represent the average and SEM of three independent experiments, each
performed in triplicate. Lines were calculated by linear regression; only uptake of
0.1 lM [3H]-diminazene by B48 expressing TbAT1 was signiﬁcantly different from
zero (P < 0.0001, F-test; r2 > 0.99). Diminazene uptake by cells expressing TbAT1was
signiﬁcantly higher than in control cells (B48 with empty vector). ⁄⁄P < 0.01;
⁄⁄⁄P < 0.001 (relative to EV control; Student’s T-test).
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lamb, 1993; De Koning and Jarvis, 1999; Collar et al., 2009). Uptake
of adenosine was increased (P < 0.001) by all three transporter
genes, relative to control (Fig. 5B). The rate of adenosine transport
was TbAT1 > TcoAT1R > TcoAT1S > control.4. Discussion
Animal African Trypanosomiasis (AAT) remains one of the ma-
jor challenges to livestock farming in sub-Saharan Africa and, as
the control of the disease is mostly through chemotherapy with a
few decades-old drugs, the large number of reports on drug resis-
tance is a cause of great concern as it threatens the sustainability of
agriculture in many areas (Geerts and Holmes, 1998; Swallow,
2000; Geerts et al., 2001; Delespaux et al., 2008a). However, it is
not clear whether the increased number of reports on diminazene
aceturate (DA) treatment failure in cattle reﬂect a spread of resis-
tant parasites, or simply a more intense focus on the problem with
more studies performed in different parts of the continent. It is dif-
ﬁcult to establish the full scale of the problem given the infrastruc-
tural and geographical challenges, particularly with the difﬁculties
in conﬁrming parasitological cure, prevention of re-infection, and
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Fig. 5. Uptake of (A) inosine and (B) adenosine in transformed T. b. brucei B48. B48 cells transformed with either vector without insert (circles), TbAT1 (squares), TcoAT1S (up
triangles) or TcoAT1R (down triangles) were incubated with 0.1 lM [3H]-inosine (A) or 0.1 lM [3H]-adenosine (B) in the presence (open symbols and dotted lines) or absence
(ﬁlled symbols and continuous lines) of 1 mM unlabeled permeant for up to 2 min as indicated. In the presence of 1 mM permeant uptake was inhibited by >99%, showing
that uptake was saturable and therefore most likely transporter-mediated. Inosine uptake by cells expressing the TcoAT1 alleles was signiﬁcantly higher than in control cells
(B48 with empty vector). Data shown are the average and SEM of three independent experiments, each performed in triplicate. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001 (Student’s
T-test). Note: in frame B each of the experimental data points were signiﬁcantly different from the empty vector control at 20 s, by P < 0.01 or better.
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use of counterfeit products and the frequent administration of vet-
erinary trypanocides by untrained people. Therefore, the most ro-
bust test for resistance has required isolation of the parasite and
testing in a standardised mouse-model (Eisler et al., 2001; Mamou-
dou et al., 2008). However, this approach is expensive and labori-
ous, and involves growth and treatment in a different animal
species, a process with its own potential selective bottlenecks.
Clearly, a molecular test for a genetic resistance marker, based
on an understanding of the resistance mechanism, has the poten-
tial to revolutionise our understanding of the spread of drug-resis-
tant parasites (Delespaux et al., 2006, 2008a). The identiﬁcation of
the P2/AT1 transporter as the principal entry route for diminazene,
and the demonstration that genetic loss of this transporter led to
substantial levels of diminazene resistance in T. b. brucei (Matovu
et al., 2003; De Koning et al., 2004), T. equiperdum (Barrett et al.,
1995), and T. evansi (Witola et al., 2004) appeared to have provided
an opportunity for a genetic test. The closest T. congolense ortho-
logue to P2/AT1 was identiﬁed from a contig database and an
SNP that statistically associated with reduced diminazene sensitiv-
ity was found (Delespaux et al., 2006). A PCR–RFLP system devel-
oped to identify the resistance-associated SNP in ﬁeld isolates
was implemented to screen for diminazene resistance in various
regions of Africa, including Cameroon (Mamoudou et al., 2008),
Eastern Zambia (Delespaux et al., 2008b), the Ghibe river basin in
Ethiopia (Moti et al., 2012) and game reserves/national parks in
Zambia, South Africa and Zimbabwe (Chitanga et al., 2011). The lat-
ter study revealed the occurrence of the ‘resistant’ PCR–RFLP mar-
ker even in regions where the drug had not been used and it has
become clear that the polymorphism initially suggested as resis-
tance-associated is common in T. congolense regardless of drug
exposure, and does not always correlate with high levels of
diminazene resistance.
We have thus undertaken a study to verify (1) whether TcoAT1
does indeed encode a P2-type transporter, (2) whether TcoAT1S
confers sensitivity to diminazene and diminazene transport capac-
ity and (3) whether there is any substantial difference in transport
phenotype between TcoAT1S and TcoAT1R. TcoAT1 alleles were
ampliﬁed and cloned from known and well-characterised T. congo-
lense isolates and veriﬁed by sequencing. We found that the TcoAT1
sequence, while closely related to TbAT1 and from the same nucle-
oside/nucleobase transporter gene family, is in fact not the ortho-
logue of TbAT1 but is the syntenic orthologue of TbNT10, a different
but well-characterised purine nucleoside transporter of the P1-
type. The P1 versus P2 distinction was ﬁrst deﬁned in T. brucei byCarter and Fairlamb (1993), where P1-type adenosine transporters
are sensitive to competitive inhibition by inosine, whereas adeno-
sine uptake by P2 is inhibited by adenine. Further characterization
showed the P1 transporters, of which the T. b. brucei genome con-
tains numerous copies (Sanchez et al., 2002; De Koning et al.,
2005), to be high afﬁnity transporters for the purine nucleosides
adenosine, guanosine and inosine (De Koning et al., 1998; De Kon-
ing and Jarvis, 1999; Sanchez et al., 2002) whereas P2 transports
only the aminopurines, adenosine and adenine (Carter and Fair-
lamb, 1993; De Koning and Jarvis, 1999). The T. b. brucei genome
appears to contain only 1 copy of TbAT1, which can be knocked
out by two rounds of homologous recombination (Matovu et al.,
2003). Numerous studies have documented the involvement of
P2 in uptake of diamidines and melaminophenyl arsenicals (see re-
views by Carter et al. (1999) and De Koning (2008)), for which the
transporter displays sub-micromolar afﬁnity (De Koning and Jarvis,
1999). In contrast, the P1-type transporters displayed two orders of
magnitude less afﬁnity for these trypanocides (De Koning and Jar-
vis, 1999) and have never been implicated in their transport.
Our observations that TcoAT1 increases sensitivity to cytotoxic
nucleoside analogues but not to diminazene, pentamidine (both
diamidines) or cymelarsan (a melaminophenyl arsenical) are con-
sistent with a classiﬁcation as P1-type transporter. Expression of
TbAT1 in the same system, used as positive control, did increase
drug sensitivity dramatically. The strong and saturable capacity
for transport of both inosine and adenosine by TcoAT1 is com-
pletely inconsistent with a P2-type activity but a hallmark of P1
(Carter and Fairlamb, 1993; De Koning and Jarvis, 1999).
In summary, we conclude that TcoAT1 encodes a P1-type trans-
porter and is not involved in diminazene uptake. It is clear that
TcoAT1 was incorrectly identiﬁed as the P2 transporter equivalent
of T. congolense, and is instead the syntenic orthologue of TbNT10
and we therefore propose that TcoAT1 be renamed TcoNT10.
Whether polymorphisms in TcoAT1/NT10, like the one identiﬁed
by the PCR–RFLP (Delespaux et al., 2006) could nonetheless be
informative with respect to diminazene resistance now seems un-
likely given that the transporter itself does not transport dimina-
zene. Several recent papers have found that this allele is present
in most T. congolense isolates from across Africa (Delespaux et al.,
2008b; Mamoudou et al., 2008; Chitanga et al., 2011; Moti et al.,
2012), leading to the conclusion that either diminazene resistance
is near-complete in the T. congolense population, or the proposed
resistance allele is a common variant of the transporter instead
of a determinant of drug sensitivity. The balance of current evi-
dence suggests the latter possibility - a conclusion strengthened
J.C. Munday et al. / International Journal for Parasitology: Drugs and Drug Resistance 3 (2013) 69–76 75by the observation that the polymorphism was found in at least 1
allele of 33 out of 34 isolates from wild-life without a history of
drug exposure (Chitanga et al., 2011). Nevertheless, we cannot rule
out the possibility that a particular TcoAT1/NT10 allele might be
associated with DA resistance through genetic linkage to a resis-
tance determinant elsewhere on the same chromosome. Mean-
while, every effort should now be made to identify the real
resistance mechanism for diminazene treatment failure in animal
trypanosomiasis, as understanding the mechanism may be rele-
vant to both the continued use of existing treatments and the
development of new trypanocides.
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